Last reviewed · How we verify
MyoCell
At a glance
| Generic name | MyoCell |
|---|---|
| Sponsor | Bioheart, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction (PHASE2, PHASE3)
- MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial) (PHASE1)
- Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial (PHASE2)
- Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MyoCell CI brief — competitive landscape report
- MyoCell updates RSS · CI watch RSS
- Bioheart, Inc. portfolio CI